Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Zymeworks Inc. (NASDAQ:ZYME) have been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $35.70.

A number of equities research analysts have commented on the company. Citigroup assumed coverage on Zymeworks in a research report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Zacks Research downgraded shares of Zymeworks from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. B. Riley Financial restated a “buy” rating and set a $40.00 price target (up from $30.00) on shares of Zymeworks in a report on Friday, November 21st. Leerink Partners upped their price objective on shares of Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Wells Fargo & Company upgraded shares of Zymeworks from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $25.00 to $33.00 in a research report on Friday, December 12th.

Zymeworks Price Performance

ZYME opened at $24.45 on Wednesday. Zymeworks has a fifty-two week low of $9.03 and a fifty-two week high of $28.49. The company’s 50 day moving average price is $23.85 and its two-hundred day moving average price is $20.95. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of -22.64 and a beta of 1.23.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $21.78 million. Zymeworks had a negative return on equity of 24.85% and a negative net margin of 76.56%.Zymeworks’s revenue for the quarter was down 91.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.31) EPS.

Insiders Place Their Bets

In other Zymeworks news, EVP Jeffrey T. L. Smith sold 9,310 shares of Zymeworks stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $211,057.70. Following the completion of the sale, the executive vice president directly owned 26,708 shares in the company, valued at approximately $605,470.36. The trade was a 25.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul Andrew Moore sold 9,560 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $22.67, for a total value of $216,725.20. Following the completion of the transaction, the insider directly owned 48,497 shares in the company, valued at approximately $1,099,426.99. This trade represents a 16.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 187,933 shares of company stock valued at $4,673,716. 33.51% of the stock is currently owned by insiders.

Institutional Trading of Zymeworks

Several hedge funds have recently modified their holdings of the stock. EcoR1 Capital LLC raised its holdings in shares of Zymeworks by 33.1% during the second quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company’s stock valued at $288,278,000 after purchasing an additional 5,710,840 shares during the period. Squarepoint Ops LLC increased its position in Zymeworks by 144.6% in the 2nd quarter. Squarepoint Ops LLC now owns 155,599 shares of the company’s stock valued at $1,953,000 after buying an additional 91,997 shares in the last quarter. Norges Bank acquired a new position in Zymeworks during the 2nd quarter worth approximately $2,531,000. Assenagon Asset Management S.A. raised its stake in Zymeworks by 169.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,326,774 shares of the company’s stock worth $22,661,000 after buying an additional 833,994 shares during the period. Finally, Tejara Capital Ltd boosted its holdings in Zymeworks by 5.7% in the second quarter. Tejara Capital Ltd now owns 200,150 shares of the company’s stock worth $2,512,000 after acquiring an additional 10,741 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Zymeworks News Summary

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Wall Street upgrades — Stifel raised its price target to $47 (buy) and Leerink Partners raised its target to $58 (outperform), both signaling strong analyst conviction and meaningful upside vs. the current price. Benzinga (Stifel) Benzinga (Leerink)
• Positive Sentiment: $250M non‑recourse royalty‑backed financing with Royalty Pharma provides immediate, non‑dilutive capital while preserving most future Ziihera royalties — improves flexibility to continue buybacks and pursue strategic moves. GlobeNewswire: Royalty‑Backed Financing
• Positive Sentiment: Commercial and milestone upside for Ziihera — partner Jazz is completing a supplemental BLA for first‑line HER2+ GEA (expected Q1 2026) with a potential 2H‑2026 launch; Zymeworks is eligible for up to ~$440M in GEA‑related milestones plus future royalties and further milestone pools. This underpins the company’s revenue runway and valuation re‑rating. GlobeNewswire: Corporate Update
• Positive Sentiment: Share‑repurchase execution — company has repurchased ~$62.5M under the authorized program to date; combined with the Royalty Pharma funding this supports near‑term buybacks and EPS accretion expectations. GlobeNewswire: Repurchase Details
• Neutral Sentiment: Earnings call & transcripts published — management reviewed strategy shift toward royalty/asset aggregation, R&D priorities and three‑year expense discipline; transcripts and presentations are available for detail (useful for modeling, but not new headlines). Yahoo Finance: Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 results missed expectations — reported EPS of $(0.55) vs. consensus $(0.35) and Q4 revenue of $2.52M (down sharply year‑over‑year). The weak quarterly revenue and continued GAAP losses are near‑term headwinds and warrant conservative near‑term models until royalties and milestone receipts ramp. Zacks: Q4 Loss & Revenue Miss

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.